Pneumococcal Vaccines in Patients With Asthma

Clinical Trial ID: NCT03260790

Description

Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.

Patients will be randomized into either PCV13 and PPSV23 (Experimental) or PPSV23 alone (Active comparator). At the Week 0 time point, the patients will receive either PCV13 (Experimental) or PPSV23 (Active comparator) and undergo a blood draw of 5ml for assessment of pre-vacation serotype titers. The Active Comparator group will undergo a 5ml draw of blood for assessment of titers at week 8, 16, and 24 following vaccination. The Experimental group will undergo vaccination with PPSV23 at week 8 with 5 ml blood draw for pneumococcal serotype titers as well as a blood draw at week 16 and week 24.


Criteria

Inclusion Criteria: - Diagnosis of asthma Exclusion Criteria: - Research exemption requested - History of PCV-13 vaccination - History of cochlear implant - Cerebrospinal Fluid (CSF) leak - Congestive Heart Failure (CHF) - Diabetes Mellitus (DM) - Chronic Kidney Disease (CKD) - Human Immunodeficiency Virus (HIV) - Common Variable Immune Deficiency (CVID) - Patients who have received the PPSV23 vaccine in the last 5 years - Women who are pregnant will also be excluded from the study by performing 2 point of care urine pregnancy tests ( prior to vaccinations)

  • Start Date

    2017-10-01

  • Last Updated

    2019-03-02

  • Sponsor

    Mayo Clinic

  • Condition Name

    Asthma

Learn about this trial.

Check the eligibility requirements, study details, and more.

Related Trials

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.